From a clinical safety perspective, individuals with a history of pancreatitis or gallbladder disease should ensure their trial clinician is aware of this, as these conditions are relevant to the risk profile of GLP-1 receptor agonist class medicines
Enquire Now Frequently Asked Questions GLP-1 Agonists Market Size is valued at USD 43.1 billion in 2024 and is predicted to reach USD 260.1 billion by the year 2034 GLP-1 Agonists Market is expected to grow at an 19.9% CAGR during the forecast period for 2025-2034
[DOI] [PMC free article] [PubMed] [Google Scholar] 114.Obligado S.H., Goldfarb D.S
GLP-1S is intended solely for research purposes
It seems we may be approaching another level with drugs like retatrutide. Furthermore, Novo Nordisk is also joining the Triple G line and reports an average weight loss of about 20% after 24 weeks in a mid-stage study of another experimental drug in China last month
For many people, these drugs have been genuinely life-changing, helping with blood sugar control, appetite regulation, and weight loss in ways that felt out of reach before
